14.04.2021Highlight Therapeutics to present data from Phase 2 immunotherapy studies of liver metastases and melanoma data at AACR Virtual Annual Meeting 202

Press Release
14.04.2021Aura Biosciences Announces Publication of Data in Cancer Immunology Research Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform with Broad Application in Cancer Treatment

Press Release
12.04.2021Francesco Maria Lavino appointed Chief Executive Officer of F2G Ltd

Press Release
01.04.2021 Eloxx Pharmaceuticals Acquires Zikani Therapeutics

Press Release
24.03.2021Aura Biosciences Expands Executive Leadership Team with the Appointment of Mark De Rosch, Ph.D., as Chief Operating Officer

Press Release
22.03.2021Aura Biosciences Announces Oversubscribed $80 Million Financing

Press Release
17.03.2021Advent Life Sciences’ founded Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Press Release
17.03.2021Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Press Release
12.03.2021Advent Life Sciences Becomes Latest Partner of One Nucleus

Press Release
02.03.2021Highlight Therapeutics and Pivotal work together on Melanoma therapy and launch a Phase IIa trial to examine BO-112 efficacy and safety

Press Release